| Endologix develops, manufactures, markets, and sells medical devices for the treatment of aortic disorders. Co.'s products are designed for the endovascular treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms: endovascular aneurysm repair (EVAR); or endovascular aneurysm sealing (EVAS), Co.'s solution for sealing the aneurysm sac while maintaining blood flow. Co.'s EVAR products include the AFX® Endovascular AAA System, the VELA® Proximal Endograft, and the Ovation® Abdominal Stent Graft System. Co.'s EVAS product is the Nellix® Endovascular Aneurysm Sealing System. We show 46 historical shares outstanding datapoints in our coverage of ELGX's shares outstanding history.|
Understanding the changing numbers of ELGX shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ELGX versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ELGX by allowing them to research ELGX shares outstanding history
as well as any other stock in our coverage universe.